Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Translating Obama For FDA

This article was originally published in RPM Report

Executive Summary

Jesse Goodman, FDA's new chief scientist and acting deputy commissioner, is in a pivotal role in the new Administration, as the bridge between the career staff at FDA and the incoming political leadership. His keynote address at the Food & Drug Law Institute Annual meeting is a must read for anyone looking for signs of how the Obama agenda will affect FDA.

You may also be interested in...



FDA's Jesse Goodman is Rising Star Within Agency

For FDA's top biologics review manager, Jesse Goodman, the announcement of the membership list of the Federal Coordinating Committee on Comparative Effectiveness Research was also his debut in a new role: acting chief medical officer. His background in infectious diseases and preparedness aligns well with the topside leadership in FDA and HHS.

FDA and Health Care Reform: An Activist Agenda for the Agency

Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.

Help Wanted: FDA Begins Search for New CDER Director

FDA has a lot of hard work ahead to make the new drug safety law a reality. Its first task: find a new director for the Center for Drug Evaluation & Research. That decision might be the most important one the agency makes in determining how the new law works.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel